The research confirmed no unconventional risks, which indicated that it could be securely administered inside a clinical research context. Later on, Dr. Charles Grob requested permission to even more review the material with cancer clients, but was denied by the FDA twice.02 Numerous variables contribute for the copyright experience, like dose, sta